Shionogi & Co., Ltd. - Unsponsored ADR (SGIOY)
OTC PINK OTC PINK Primary 
Shionogi & Co., Ltd. (SGIOY) Q1 2025 Earnings Call Transcript
Shionogi & Co., Ltd. (OTCPK:SGIOY) Q1 2025 Earnings Conference Call July 28, 2025 3:30 AM ET Company Participants John A.
SGIOY or ZTS: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Drugs sector might want to consider either Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) or Zoetis (ZTS).
SGIOY or ZTS: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) and Zoetis (ZTS).
Shionogi & Co., Ltd. (SGIOY) Q3 2024 Earnings Call Transcript
Shionogi & Co., Ltd. (OTCPK:SGIOY) Q3 2024 Earnings Conference Call January 31, 2025 3:30 AM ET Company Participants Yoshimasa Kyokawa - VP, Corporate Communications Masako Kudou - VP, Finance & Accounting Department Kazuhiro Hatanaka - Senior Executive Officer, Corporate Supervisory Unit & Corporate Strategy Division Toshinobu Iwasaki - SVP, Healthcare Business Unit Takeki Uehara - SVP, Drug Development & Regulatory Science Division Conference Call Participants Hidemaru Yamaguchi - Citi Eiji Ueda - Goldman Sachs Fumiyoshi Sakai - UBS Kazuaki Hashiguchi - Daiwa Securities Shinya Tsuzuki - Mizuho Securities Shinichiro Muraoka - Morgan Stanley Seiji Wakao - JPMorgan Yoshimasa Kyokawa This is Kyokawa of the Corporate Communication Department of Shionogi.
Shionogi & Co. (SGIOY) Upgraded to Buy: What Does It Mean for the Stock?
Shionogi & Co. (SGIOY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Shionogi & Co., Ltd. (SGIOY) Q2 2024 Earnings Call Transcript
Shionogi & Co., Ltd. (OTCPK:SGIOY) Q2 2024 Earnings Call Transcript October 29, 2024 2:00 AM ET Company Participants Yoshimasa Kyokawa - Vice President, Corporate Communications Isao Teshirogi - Chairman, President, and CEO John Keller - Senior Vice President, R&D, Supervisory Unit Takeki Uehara - Senior Vice President, Drug Development and Regulatory Science Division Toshinobu Iwasaki - Senior Vice President, Healthcare Business Unit Koji Hanasaki - Senior Vice President, Supply Supervisory Unit, Global Business Division Masako Kudou - Vice President, Finance and Accounting Department Conference Call Participants Hidemaru Yamaguchi - Citi Eiji Ueda - Goldman Sachs Kasumi Haruta - UBS Kazuaki Hashiguchi - Daiwa Securities Seiji Wakao - JPMorgan Shinya Tsuzuki - Mizuho Securities Miki Sogi - Bernstein Hiroyuki Matsubara - Nomura Securities Yoshimasa Kyokawa Ladies and gentlemen, time to start today's meeting.
